Scientific topics
Keywords
Emmanuelle Comets PhD in Biomathematics
Course and current status
Current position (since 2002): Researcher (CRCN) at INSERM, National Institute of Health and Medical Research, France
2022-present: INSERM IAME UMR 1137, Bichat Hospital, Paris, France (Université Paris Cité and Université Sorbonne Paris Nord, Inserm) et INSERM UMR_S 1085, Rennes, France (Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)
2014-2022: INSERM IAME UMR 1137, Bichat Hospital, Paris, France (Université Paris Cité and Université Sorbonne Paris Nord, Inserm) et CIC 1414, Rennes, France (Univ Rennes, Inserm)
2002-2014: INSERM UMR 738, Bichat Hospital, Paris, France
2010: Habilitation à diriger des recherches, Université Paris-Diderot - Paris VII, France (Etude de la réponse aux médicaments par la modélisation des relations dose-concentration-effet)
2000-2002: Post-doctorate fellow, Keio University Hospital, Tokyo, Japan
1997-2000: PhD in Biomathematics, University Pierre et
Marie Curie, Paris VI, France (Supervisor: Pr France Mentré, Topic: PK/PD model of long-acting release formulations of octreotide)
1994-1996: Ingénieur en Agronomie, Institut National Agronomique Paris Grignon, France
1991-1994: Ingénieur de l'Ecole Polytechnique, Ecole Polytechnique, Palaiseau, France
Scientific summary
My area of research consists in developing mathematical and statistical models to describe the dose-concentration-response relationships of drugs. This area of research has become known recently as Pharmacometrics.
I work mostly on longitudinal data, using nonlinear mixed effect models to describe the time-course of the observed processes. My main methodological developments concern the building and evaluation of these models, with a particular emphasis on pharmacogenetics. I'm also interested in design optimisation and algorithms for parameter estimation.
My daily work includes applying these approaches to data from clinical or experimental trials, in particular in the area of anticoagulant drugs, haematology, cancer and rheumatology.
